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SIX5A differential CpGmethylation proﬁle upstream of the expanded CTG array at theDMPK locus has been reported
in patientswithmyotonic dystrophy type 1 (DM1), suggesting that hypermethylationmightmodulate DM1phe-
notype, possibly affecting expression levels of DMPK and/or ﬂanking genes. To clarify this issue, we characterized
by methylation sensitive high resolution melting (MS-HRM) the CpG methylation pattern of DNA sequences
ﬂanking the pathological CTG expansion in 13 childhood-onset, 37 juvenile/adult-onset, 7 congenital DM1 pa-
tients carrying uninterrupted CTG expansions and in 9 DM1 patients carrying variant expansions vs 30 controls.
Association of methylation status with disease features (nCTG, age, sex, MIRS, disease duration) was also
assessed. Finally, DMPK and SIX5 expression levels were evaluated in leukocytes from controls, methylated and
unmethylated DM1 patients.
We found hypermethylation involving upstream sequences of DM1 locus in patients with uninterrupted CTG ex-
pansions N1000 CTG and affected by a congenital or childhood onset form. Besides the n(CTG) and early disease
onset, hypermethylation was also signiﬁcantly associated with maternal transmission.
On the other hand, hypermethylation involved the 3′ of the CTG array in DM1 patients carrying variant expan-
sions. DMPK and SIX5 expression did not signiﬁcantly differ in methylated vs unmethylated DM1 patients. Our
results suggest that either the inherited size of the expanded allele and the presence of interruptions at the 3′
end are associated with a highly polarized pattern of CpGmethylation at the DM1 locus and that, at least in leu-
kocytes, DM1 locus hypermethylation would not signiﬁcantly affect DMPK or SIX5 expression.
© 2015 Elsevier B.V. All rights reserved.scale; CTG, cytosine–thymine–
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Myotonic dystrophy type 1 (DM1, dystrophia myotonica, Steinert's
disease; OMIM 160900), themost common form of adult-onset muscu-
lar dystrophy in humans, is characterized bymuscle weakness, wasting
and myotonia [1].
The clinical spectrum of DM1 patients is highly variable including
congenital and childhood onset cases with the most severe phenotype
characterized mainly by cognitive impairment, the adult-onset where
the core features are facialweakness, myotonia and distalmuscleweak-
ness, and the late-onset or oligosymptomatic patients where only limit-
ed features are found [1].
The disease is caused by an expansion of repetitive CTG sequences in
the 3′ untranslated region of DMPK gene on chromosome 19q13.3 [2,3].
Unaffected individuals have 5–37 CTG repeats, whereas DM1 patients
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matic mosaicism in tissues [1]. The present consensus is that expanded
non-coding CTG tract is transcribed, and the expression of long CUG se-
quences in the mutant DMPK transcripts contribute to DM1 pathology
through a RNA gain of function mechanism [4]. The DMPK expanded
transcript accumulates in the nucleus in ribonuclear foci and interferes
with RNA-binding proteins, leading to decreased functional levels of
muscleblind-like proteins (MBNLs) [5–8] which are sequestered in the
foci, and also increasing the steady-state levels of CELF1 (CUGBP1 and
ETR-3-like factor) [9]. The main consequence of this toxic RNA function
in DM1 tissues is a widespread splicingmysregulation ofmultiple genes
(“spliceopathy”) in which embryonic isoforms are expressed in adult
muscle, heart and brain with potential serious and life-threatening
manifestations [10].
In addition to “spliceopathy,” RNA toxicity in DM1 may trigger dif-
ferent pathogenic mechanisms including dysregulation of transcription
and microRNA metabolism, defects in protein translation/turnover and
activation of cellular stress and apoptotic pathways [11–14].
A role for epigenetic alterations in DM1 has also been proposed, ei-
ther as a mechanism to explain intergenerational or somatic repeat in-
stability or as an explanation for the altered expression of the DMPK
transcript itself and of adjacent genes [15].
The DM1 CTG repeat lies in a gene-enriched region of chromosome
19 and is embedded in a large 5.5 kb CpG island contiguous with the
promoter region of the downstream SIX5 gene [16,17].
The CTG repeat itself is surrounded by two binding sites for the chro-
matin insulator CTCF, a multifunctional zinc ﬁnger protein that binds to
DNA inﬂuencing gene expression, nucleosome positioning and chroma-
tin packaging [18]. Additional complexity ariseswithproductionof an an-
tisense transcript that initiates within the SIX5 promoter and extends
back through the DM1 repeat, producing a CAG-containing RNA able to
induce transcriptional silencing (RITS) and heterochromatin formation
[18]. Thus, large CTG expansions and their accompanying chromatin
changes can potentially trigger three alternative pathogenic pathways:
decreased gene expression due to RITS, loss of CTCF binding and aberrant
transcription around CTG repeat, transcription of long CAG-containing
RNA that may be toxic independently of DMPK expression [18].
About epigenetic methylation of DM1 locus, available data are very
limited and controversial.
By methylation-sensitive restriction analysis, an early study on leu-
kocytes DNA of DM1 patients, including both congenital, adult-onset
forms and controls, showed that the SacII site at theDMPK locus located
over 1 kb upstream of the CTG repeat results constitutively methylated,
without evidence of genomic imprinting or hypermethylation for DM1
alleles [19].
In contrast, later studies documented hypermethylation of expand-
ed DM1 alleles in correspondence of several CpG sites upstream of the
CTG repeat but not involving the methylation sensitive CTCF binding
site [20,21]. These studies obtained conﬂicting results concerning corre-
lations between the methylation status of DM1 allele in leukocytes and
age at onset, disease severity or n(CTG) [19–21]. More recently, López
Castel et al., [22] assessedmethylation, using amore sensitive bisulphite
sequencing PCR, not in leukocytes but in fetal and adult DM1 autoptic
tissue samples as well in tissues of a DM1 transgenic mouse [22].
Using this approach, tissue-, age- and DNA region speciﬁc variations in
CpG methylation of the expanded alleles were speciﬁcally observed in
DM1 tissues, polarized in the region upstream to the CTG expanded
tract. This study suggested that hypermethylation would be age depen-
dent, being higher in fetal vs adult tissues, and also documented inter
and intra-individual variability in methylation levels not obviously re-
lated to the size of n(CTG) present in tissues. On the other hand, expres-
sion of DMPK and of adjacent genes in correlation to methylation status
was not assessed in this study [22].
The CTG repeat atDMPK locus is usually uninterrupted in both healthy
and expanded alleles, however so called “variant” repeats containing un-
stable CCG, CTC and CGG sequence interruptions at the 3′-end of the CTGarray can be detected in a lowpercentage (3–5% of cases) of DM1patients
[23–26]. The presence of interruptionswithin anotherwisehomogeneous
tract of repeats has been associated with a number of TREDs including
FRAXA [27], SCA1 [28], SCA2 [29] and FRDA [30,31]. In general, repeat in-
terruptions lead to a stabilizing effect because of their ability to disrupt the
formation of unusual DNA structures formed by “pure” repetitive se-
quences [32]. Nodata are available regarding their in cis effects on the epi-
genetic changes occurring at the DM1 locus. Based on these premises, we
designed this study in order to 1) assess themethylation status upstream
and downstream of the unstable CTG tract at DM1 locus, encompassing
CTCF binding sites, in leukocytes DNA obtained from the largest cohort
of DM1 patients reported so far, including both uninterrupted and variant
expansions (n= 66) in comparison to age-matched controls (n= 30),
2) verify if any association exists between methylation status at DM1
locus in leukocytes and speciﬁc clinical and molecular disease features,
and 3) evaluate the effects ofmethylation onDMPK and SIX5 gene expres-
sion in leukocytes.
We used methylation sensitive-high resolution melting (MS-HRM)
technique, a novel approach that allows semi-quantitative assessment
of methylation levels in a locus-speciﬁc manner comparing the melting
proﬁles between methylated and unmethylated DNA.
2. Materials and methods
2.1. Patients
Genetically conﬁrmed DM1 patients were selected from the large
collection studied primarily for diagnostic purposes at Catholic and
Tor Vergata Universities (Rome, Italy) over the years.
This cohort includes 66DM1patients (age 38.6±12.5 years), and 30
age-matched healthy controls (age 40.3± 13.8 years). The study design
fulﬁlled the guidelines of the Ethical Boards of our Institutions.
2.2. DNA extraction
Genomic DNAwas extracted fromperipheral blood leukocytes using
“salting-out” modiﬁed method [33]. 10 ml of anti-coagulated blood
(EDTA) were resuspended in 50 ml polypropylene centrifugation
tubes with 40 ml of lysis buffer (0.32 M sucrose, 10 mM Tris, 5 mM
MgCl2 and 1% TritonX). After centrifugation (4 °C) at 5000 rpm for
30 min, the pellet was digested overnight at 37 °C with Kern solution
(10 mM Tris–HCl, 400 mM NaCl and 2 mM EDTA) 0.2 ml of 10% SDS
and 0.5 ml of a protease K solution (1 mg protease K in 1% SDS and
2 mM Na2EDTA). After digestion was complete, 1 ml of saturated NaCl
(approximately 6 M) was added to each tube and shaken vigorously
for 15 s, followed by centrifugation (4 °C) at 7000 rpm for 30 min. The
precipitated protein pellet was left at the bottom of the tube and the su-
pernatant containing the DNA was transferred to another 15 ml poly-
propylene tube. Exactly 2 volumes of room temperature absolute
ethanol was added and the tubes inverted several times until the DNA
precipitated.
The precipitatedDNA strandswere removedwith a plastic spatula or
pipette and transferred to a 1.5 ml microcentrifuge tube containing
100–200 μl TE buffer (10 mM Tris–HCl, 0.2 mM Na2EDTA, pH 7.5). The
DNA was allowed to dissolve 2 h at 37 °C before quantitating.
The genomic DNA was quantiﬁed by the Qubit® 2.0 Fluorometer
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer's
instructions.
2.3. Bisulphite conversion
Bisulphite treatment of DNA converts all unmethylated cytosines
to uracil, leaving methylated cytosines unaltered. Genomic DNA
(2 μg in 20 μl) was treated with EZ DNA Methylation-Gold Kit
(Zymo Research, Irvine, CA, USA) according to the manufacturer's
instructions.
2647M. Santoro et al. / Biochimica et Biophysica Acta 1852 (2015) 2645–2652After bisulphite conversion, the genomic DNAwas quantiﬁed by the
Qubit® 2.0 Fluorometer (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer's instructions.
2.4. Methylation sensitive high resolution melting (MS-HRM)
High resolution melting technology is based on the comparison of
the melting proﬁles of sequences that differ in base nucleotide compo-
sition. The PCR product originating from the methylated allele will
have different GC content fromPCR product derived fromunmethylated
variant of the same locus [34]. TheDMPK gene region studied is detailed
in Fig. 1A.
In order to reduce the complexity of themelting proﬁle and to max-
imize the melting temperature (Tm) difference between methylated
and unmethylated allele, we ampliﬁed sequence around 70–60 bp di-
viding the upstream region of CTG array into three amplicons indicated
as CSP1(11 CpG sites), CSP2 (8 CpG sites) and CSP3 (11 CpG sites)
(Fig. 1A) and the downstream region into two amplicons indicated as
CSP4 (8 CpG sites) and CSP5 (5 CpG sites) (Fig. 2A).
Primers for bisulphite-modiﬁed DNA were designed using Methyl
Primer Express Software v1.0 (Applied Biosystems, Foster City, CA,
USA) (Supplementary Table S1). The standard curve to quantify methyl-
ation percentages were established at 0%, 10%, 25%, 50%, and 100%Fig. 1.Methylation analysis of the region upstream of the CTG repeat at the DMPK locus by HRM
bars, CTCF1 binding site as black box, CTG repeat region as gray box and intronic sequences as t
treated from leukocytes of DM1 patients was ampliﬁed using CSP1F/CSP1R for CSP1(11 CpG site
tract. B) Up-panel, aligned melt curve proﬁles of standard templates (0%, 25%, 50% and 100%);
[Pt49 (adult onset DM1 with uninterrupted CTG expansions), Pt57 (congenital DM1 with unin
ruptions at 3′-end of the CTG array) and a healthy control]. The corresponding melting proﬁle
region upstream of the CTG repeat in cDM1 and DM1 patients with large expansion; no meth
and in the control.methylation using the EpiTect PCR Control DNA kit (Qiagen, Germany).
The standard curve with known methylation ratio was included in each
run. MS-HRM was performed using StepOnePlus thermocycler (Applied
Biosystems, Foster City, CA, USA). The reaction mix (total volume of
20 μl), contained 20 nanograms (ng) of bisulphite-treated DNA, 0.5 μM
of either forward/reverse primers and 1× of MeltDoctor HRM Master
Mix (Applied Biosystems, Foster City, CA, USA). Thermal cycling consisted
of enzyme activation of 10min at 95 °C, followed by 40 cycles of each PCR
step: (denaturation) 95 °C for 15 s and (annealing/extension) 60 °C for
1min. Finally, melt curve/dissociation: denaturation at 95 °C for 10 s, an-
nealing at 60 °C for 1 min, high resolution melting at 95 °C for 15 s and
annealing at 60 °C for 1 min.
To obtain the methylation percentage of each sample, DNA melting
curves were analyzed using high resolution melting software 3.1 (Ap-
plied Biosystems, Foster City, CA, USA) that compare themelting proﬁle
of each samples with standard curve. Each sample was assessed in
triplicate.
2.5. CpG methylation analysis by SacII, HpaII and HhaI restriction enzymes
In order to discriminate the presence of methylation from the non-
expanded DM1 alleles (upstream and downstream of CTG array), we
performed on methylated DM1 samples (detected by HRM) a PCR. A) Genomic structure upstream of the CTG repeat. The CpG islands are pictured as pink
hick black line. The PCR primers used in this study are indicated as arrows. DNA bisulphite
s) tract, CSP2F/CSP2R for CSP2 (8 CpG sites) tract and CSP3F/CSP3R for CSP3 (11 CpG sites)
lower panel aligned melt curve proﬁles of representative sample of DM1 patients studied
terrupted CTG expansions), Pt64v (DM1 with variant CTG expansions carrying CCG inter-
s are indicated by arrows. HRM documented hypermethylation of expanded alleles at the
ylation of this region was detected in the DM1 patient with variant expansions (Pt64v)
Fig. 2.Methylation analysis of the region downstream of the CTG repeat at the DMPK locus by HRM. A) Genomic structure downstream of the CTG repeat. The CpG islands are pictured as
pink bars, CTCF2 binding site as black box, CTG repeat region as gray box and intronic sequences as thick black line. The PCR primers used in this study are indicated as arrows. DNA
bisulphite treated from leukocytes of DM1 patients was ampliﬁed using CSP4F/CSP4R for CSP4 (8 CpG sites) tract, CSP5F/CSP5R for CSP5 (5 CpG sites) tract. B) Up-panel, aligned melt
curve proﬁles of standard templates (0%, 25%, 50% and 100%); lower panel aligned melt curve proﬁles of representative sample of DM1 patients (Pt49, Pt57, Pt64v) and a healthy control.
The correspondingmelting proﬁles are indicated by arrows. In the downstream region (CSP4, CSP5)HRMdocumented hypermethylation of expanded alleles only in the DM1 patientwith
variant expansions (Pt64v), whereas no methylation of this region was detected in DM1 and cDM1 patients with uninterrupted CTG expansions as well as in the control.
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digestion (SacII, HpaII and HhaI). Upstream region of the CTG repeat:
50 ng of genomic DNA were ampliﬁed in a reaction volume of 20 μl,
using 2.5 units of MyTaq DNA polymerase (Bioline, USA), 5×MyTaq re-
action buffer (Bioline, USA), 20mMof each primers forward (SDM-F) 5′
GCTCCAGTCCTGTGATCCGGG-3′ and reverse MDYZ2A [35].
Cycling conditions were: 2min/95 °C, initial denaturation; 15 s/95 °C,
30 s/65 °C, 30 s/72 °C for 30 cycles; 10min/72 °C, ﬁnal extension. The PCR
products were digest with 3 units of SacII (unique site 42 bases upstream
of the CTG repeat) for 2 h at 37 °C. Downstream region of the CTG repeat:
weperformed the samePCR ampliﬁcation protocol but usingMDY1Dand
MDYZ2A primers [35]. The PCR products were digest with 3 units of each
HpaII/HhaI (in the downstream region of the CTG repeat are present two
HpaII sites and one HhaI site) restriction enzymes in double digestion. All
PCR products were run in 2% agarose-gel electrophoresis.
2.6. Quantitative Real-Time PCR (qRT-PCR)
We performed a standard qRT-PCR analysis to determine relative
mRNA transcript levels of DMPK and SIX5 in a representative sample
of DM1 patients (Pt1, Pt17, Pt22, Pt28, Pt32, Pt52, Pt53, Pt56, Pt62 and
Pt64) and seven healthy controls after informed consent.
Total RNA was extracted from peripheral blood leukocytes using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA), according to the
manufacturer's instructions. First strand cDNA was synthesized using1 μg of total RNA DNase I treated, 100 ng oligo(dt)12–18 primer
(Invitrogen), 0.5 mM dNTPs and 200 units SuperScript II reverse tran-
scriptase (Invitrogen) at 42 °C for 1 h.
qRT-PCR was performed using TaqMan Universal Master Mix II
(Applied Biosystems) and TaqMan probe assays for DMPK
(Hs00189385_m1, Applied Biosystems), for SIX5 (Hs01650774_m1, Ap-
plied Biosystems) and β-actin (Hs99999903_m1, Applied Biosystems).
Thermal cycling conditions on StepOnePlus thermocycler (Applied
Biosystems) consisted of holding stage at 50 °C for 2 min and 95 °C for
10 min followed by 40 cycles of each PCR step: (denaturation) 95 °C
for 15 s and (annealing/extension) 60 °C for 1 min.
The relative fold-change 2−ΔΔCT method was used to determine the
relative quantitative gene expression compared with β-actin as endog-
enous control. All PCR reactions were performed in triplicate and a neg-
ative control was included that contained primers without cDNA. Data
were expressed as the mean ± standard error (SE).2.7. Statistical analysis
A descriptive analysis was conducted to show the characteristics of
the DM1 patients at the time of diagnosis. For statistical analysis, we di-
vided our DM1 cohort into methylated patients, when subjects had 5%
methylation or more in at least one of the 5 amplicons studied in the
CTG array, and unmethylated patients, if the subjects had nomethylation
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groups (onset ≤18 or N18 years).
Chi-square and Fisher's exact testswere used to compare the distribu-
tions of numerical (age, lower value of nCTG range detected in leukocytes,
MIRS) or categorical variables (gender, disease onset, transmission of the
mutation) between methylated and unmethylated patients respectively;
p values of b0.05 were considered to indicate signiﬁcant differences.
We then performed a logistic regression analysis to assess the effect of
selected covariates (gender, disease onset, transmission of the mutation,
nCTG, MIRS) on methylation status. Final adjusted odds ratio (AORs)
were adjusted for disease onset and transmission of the mutation.
Statistical analysis was performed using Stata software
(StataCorp. 2013. Stata Statistical Software: Release 13. College Sta-
tion, TX: StataCorp LP).3. Results
3.1. CpG methylation in DM1 patients with pure CTG expansions
Methylation analysis was focused upon regions immediately
ﬂanking unstable CTG tract: these include 30 CpG sites upstream and
13 CpG sites downstream from the CTG repeat, respectively (Figs. 1A
and 2A). The standard melting curves obtained for different ratios of
methylated-to-unmethylated templates (0%, 10%, 25%, 50% and 100%)
are shown (Figs. 1B and 2B, upper panels). The aligned melt curve pro-
ﬁles of standard methylated genomic DNA and of representative DM1
and control samples are also displayed (Figs. 1B and 2B, lower panels).
In agreement with previous data [19–22], we found that in controls
DMPK locus is invariably unmethylated, either upstream and down-
stream of the CTG array (data not shown).
In DM1 patients carrying uninterrupted CTG expansions we also
found hypermethylation (15%–50%) involving the upstream region of
the CTG repeat in particular hypermethylation was found in all congen-
ital, in six out of thirteen childhood onset and in only six out of thirty-
seven adult-onset DM1 patients (Fig. 1B; Table 1).
Methylated DM1 patients harbored larger CTG expansions than
unmethylated ones (p b 0.001). Hypermethylation was also signiﬁcant-
ly associated with onset of symptoms ≤18 years (p b 0.001), andmater-
nal origin of the expanded allele (p b 0.001). In contrast, neither diseaseTable 1
Sociodemographic characteristics of 57 DM1 patients by methylation status.
Methylated group
(n= 19)
Unmethylated group
(n= 38)
p value
n % n %
Gender
Women 7 36.8% 17 44.7% 0.569
Men 12 63.2% 21 55.3%
Age at initial symptoms
Adult 6 31.6% 31 81.6% b0.001
Child 6 31.6% 7 18.4%
Congenital 7 36.8% 0 0.0%
Mutation
Paternal 2 11.8% 21 67.7% b0.001
Maternal 15 88.2% 10 32.3%
nCTG
b1000 6 31.6% 38 100.0% b0.001
≥1000 13 68.4% 0 0.0%
MIRS
1 1 5.3% 2 5.3% 0.254
2 1 5.3% 7 18.4%
3 10 52.6% 18 47.4%
4 5 26.3% 11 28.9%
5 2 10.5% 0 0.0%
MIRS = Muscular Impairment Rating Scale [36].severity measured by MIRS nor patients' age showed a signiﬁcant asso-
ciation with methylation status of DM1 locus.
The AORs (95% CI) were 9.42 (1.66–53.44) and 21.91 (3.16–151.76)
for disease onset and transmission of the mutation, respectively
(Table 2).
3.2. CpG methylation in DM1 patients with variant expansions
In order to investigate if the presence of the CCG, CTC and CGG se-
quence interruptions in the 3′-end of the CTG array might lead to mod-
iﬁcations in the levels and/or pattern ofmethylation,we performedMS-
HRMonnineDM1patientswith variant repeats previously diagnosed in
our laboratories [26] (Table 3). Six of them also showed high methyla-
tion levels (range 15%–50%) that, however, did not involve the CpG is-
land at the 5′ end of the repeat, as observed in “uninterrupted” DM1
patients, but only the region downstream of the CTG array (Fig. 2B;
Table 3). Interestingly, these patients had a number of CGG interrup-
tions along the CTG array more abundant compared to variant
unmethylated patients (Table 3).
3.3. CpG methylation is limited to the DMPK expanded allele
To test whether the methylation detected byMS-HRM in DM1 sam-
ples was speciﬁc to the disease allele, we digested PCR products using
methylation-sensitive enzymes SacII, HpaII and HhaI.
We ampliﬁed the region of interest in our methylated DM1 samples
using SDM-F (forward) and MDYZ2A (reverse) primers annealing on
the opposite sides of the CTG repeat and capable of amplifying only
the non-expanded DMPK allele by short-PCR conditions [35] (Fig. 3A,
upper panel). These two primers amplify a PCR fragment from the
non-expanded allele (397 bp) which includes a SacII site, located
42 bp upstream of the CTG tract (Fig. 3A, upper panel).
SacII digestion, indeed produced two PCR bands of 335 bp and 62 bp
(Fig. 3A, lower panel), being indicator of a non-methylated template. In
variant DM1 patients, we used MDY1D (forward) and MDYZ2A (re-
verse) primers [35], by short-PCR conditions to amplify the region of a
303 bp fragment that contain twoHpaII and oneHhaI sites downstream
of the CTG tract only fromwild-type alleles (Fig. 3B, upper panel). Dou-
ble digestion of PCR products with HpaII/HhaI raised four fragments of
150 bp, 110 bp, 23 bp and 20 bp indicating that ampliﬁed fragment
from the wild-type allele is not methylated also in these patients
(Fig. 3B, lower panel). We conclude that the high levels of CpG methyl-
ation detected by MS-HRM depend exclusively from expanded alleles.Table 2
Univariate and multivariate analysis of selected variables and methylation status of DM1
patients.
Univariate analysis Multivariate analysis
OR CI 95% OR# CI 95%
Gender
Women Ref Ref
Men 1.39 0.45–3.30 0.70 0.13–3.89
Disease onset
Adult Ref Ref
Child 9.59 2.70–34.11 9.42 1.66–53.44
Mutation
Paternal Ref Ref
Maternal 15.75 3.00–82.54 21.91 3.16–151.76
nCTG
b1000 Ref Ref
≥1000 nc§ nc§
MIRS 1.55 0.79–3.05 1.26 0.45–3.53
OR, odds ratio; CI, conﬁdence interval; MIRS =Muscular Impairment Rating Scale [36].
# Odds ratio adjusted for disease onset, and mutation.
§ Not computable, presence of a cell value equal to zero.
Table 3
DM1 patients with interruptions in the primary structure of the 3′-end of the CTG array and methylation status.
Patient
(Pt)
n(CTG) Age of
examination
(years)
Disease onset MIRS Parental origin
of mutation
CSP4
(%)
CSP5
(%)
Sequence of the interruptions
Pt58 118 37 Adult 3 Maternal 0% 0% (CTG)32CCG(CTG)2CCG(CTG)6(CCG)2(CTG)2CCG(CTG)5CCG(CTG)25(CTG)31
(CCG)2(CTG)2CCG(CTG)22CCG(CTG)34(CCG)2(CTG)2CCGCTC(CTG)4
Pt59 400–580 61 Adult 3 Paternal 25–50% 0% (CCGCTG)7TCGCTG(CCGCTG)7(CTG)20
Pt60 450–550 24 Asymptomatic 1 Maternal 25–50% 10–25% (CTG)16CCG (CTG)2(CCGCTG)4CTG[(CCGCTG)4CCG]2(CCGCTG)5(CTG)22
Pt61 475–640 33 Adult 2 Paternal 0% 0% (CTG)2 G (CTG)9 G (CTG)20(CTG)23TTG(CTG)4
Pt62 550–700 65 Adult 3 Paternal 25–50% 10–25% (CTG)5(CCGCTGCTG)46
Pt63 600–700 35 Adult 2 Paternal 0% 0% (CTG)68CCG(CTG)9
Pt64 600–830 55 Adult 2 Paternal 25–50% 25–50% (CTG)9(CCGCTGCTG)61
Pt65 740–930 51 adult 3 Paternal 10–25% 0% (CCGCTG)2(CCG)2(CTG)3(CCGCTG)3(CTG)7(CCGCTG)18
Pt66 970 32 Child 3 Maternal 25–50% 25–50% (CTG)12CCG (CTG)6CCG(CTG)5CCG(CTG)5
MIRS = Muscular Impairment Rating Scale [36]. CSP4 and CSP5 amplicons are referred to the methylation percentage into downstream region of CTG array.
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Three out of ﬁve unmethylated DM1 patients (Pt17, Pt1 and Pt32)
showed a 2–3 fold increase in the expression levels of SIX5 compared
to controls, while in the other two (Pt22 and Pt28) the levels were nor-
mal (Fig. 4). A 50% reduction inDMPK RNA levels was found in three pa-
tients (Pt1, Pt28 and Pt32) compared with controls, while in the other
two patients (Pt17 and Pt22) DMPK RNA levels were normal (Fig. 4).
Two cDM1 patients with hypermethylation at the 5′-end of the CTG
array (Pt52 and Pt56) showed expression levels of SIX5 and DMPK com-
parable to controls, while in one of them (Pt53) SIX5 RNA levels were 2-
fold higher (Fig. 4).
Of the two variant DM1patients studied, one (Pt62v) showed higher
levels of SIX5, whereas the other (Pt64v) showed a reduction in the ex-
pression levels of DMPK compared to controls (Fig. 4).
T-Student's test documented a signiﬁcant difference in the ex-
pression of both DMPK (p = 0.03) and SIX5 (p = 0.006) in all DM1
patients vs controls, however the expression of the two genes didFig. 3. Analysis of methylation allele speciﬁcity. A and B) Upper panel, genomic structure of the
black line. The PCR primers are indicated as arrowswhile the restriction fragments as dashed lin
product (397 bp) from only the non-expanded CTG allele. Following SacII digestion the presenc
allele was not methylated in the DM1 and cDM1 patients (Pt49 and Pt57, respectively) which
primers [35] produced a PCR product of 303 bp. Double digestion with HpaII/HhaI showed fou
in the non-expanded allele was not methylated in the DM1 with variant expansions (Pt64v a
the high levels of CpG methylation detected by HRM (upstream and downstream of the CTG anot correlate with the CpG methylation levels of the CTG array.
(DMPK p = 0.1; SIX5 p = 0.4).
4. Discussion
The role and the pathogenic consequences of epigenetic modiﬁca-
tions associated with pathological expansion of the CTG array at DM1
locus are still poorly understood. In order to clarify this issue, in this
work we assessed the CpG methylation proﬁle of the regions upstream
and downstream of the CTG expanded tract in a well characterized co-
hort of 66 DM1 patients, being the largest reported so far and including
also DM1 patients carrying variant expansions with CCG/CTC/CGG in-
terruptions at the 3′-end of the expanded CTG array.
Differently from previous studies [19–22] that used methylation-
sensitive restriction analysis to assess methylation at the 5′ side of
DM1 locus, we used MS-HRM which allowed us to accurately estimate
the percentage of methylation in the region of interest, including also
those CpG sites not detected by MS-restriction analysis. MS-HRMCTG array. The CTG repeat region is presented as black box and intronic sequences as thick
es. A) Upstreamprimer (S-DM F) and downstreamprimer (MDYZ2A) [35] produced a PCR
e of two bands (335 bp and 62 bp, lower panel) revealed that this site in the non-expanded
by HRM analysis showed high levels of upstream methylation. B) MDY1D and MDYZ2A
r PCR products of 150 bp, 110 bp, 23 bp and 20 bp (lower panel) indicating that this site
nd Pt59v) which by HRM analysis showed high levels of downstream methylation. Thus,
rray) were exclusively present on the expanded DM1 allele.
Fig. 4. Real-Time qRT-PCR analysis of SIX5 and DMPK mRNA expression. qRT-PCR to determine relative mRNA transcript levels of SIX5 and DMPK in child/adult onset DM1 patients
(Pt1, Pt17, Pt22, Pt28 and Pt32, hypomethylation), cDM1 patients (Pt52, Pt53 and Pt56, hypermethylation at 5′-end of CTG expansion), DM1 with CCG interruptions at the 3′-end of
the expanded CTG array (Pt62v and Pt64v, hypermethylation at 3′-end of CTG expansion) and 7 healthy controls. Values were normalized to expression levels of β-actin and were the
mean of three experiments ±standard error (SE).
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quences that differ in base composition [34]. In fact, the PCR product
originating from themethylated allele have a different sequence consti-
tution (GC content) from the PCR product derived from unmethylated
variant of the same locus. As a consequence, both products have distinct
melting temperature andmelting proﬁles [34]. This technique allows to
obtain detailed information about global methylation (not single CpG
islands) levels of the sequence ampliﬁed with similar results to those
obtained by pyrosequencing [37].
So far, only one study [22] analyzed the sites of CpGmethylation up-
stream and downstream to the CTG repeats by direct sequencing. Al-
though this method is probably the most accurate, because it allows
analyzing any single CpG islands, it has very high costs especially if it
has to be applied to the study of large genomic regions of a broad pop-
ulation, like the one reported in this study.
ByMS-HRM,we conﬁrmed that DM1 is associatedwith changes in the
methylation levels of the expanded allele [19–22]. For uninterrupted al-
leles, we documented that hypermethylation occurs only in the upstream
region of the CTG repeat, and this modiﬁcationwas signiﬁcantly associat-
ed with larger nCTG (N1000) and earlier age at onset (b18 years)
(Table 2): indeed, we found hypermethylation in all congenital DM1, in
about half of childhood onset DM1 patients but only in six out of thirty-
seven adult onset DM1 patients (Table 1).
Taken together these ﬁndingswould suggest thatmethylationmight
be an early occurring phenomenon in DM1 patients carrying uninter-
rupted alleles, possibly driven by the inherited size of the expanded al-
lele. In this regard, the association of hypermethylation with congenital
or childhood onset forms, both of which share predominant cognitive
manifestations, would suggest that this epigenetic modiﬁcation might
affect by still unknownmechanisms, the expression of genes regulating
brain development or synaptic plasticity.
Hypermethylation at DM1 locus was signiﬁcantly associated with ma-
ternal transmission of the DM1 mutation. In this regard the exclusively
maternal transmission of the congenital forms [1] could have represented
a bias, although our cohort of patients included the whole phenotypic
spectrum of DM1, andmultivariate analysis supports a speciﬁc association
between methylation and mutation maternally transmitted (Table 2).
Recent literature data supports age-associated global hypomethyla-
tion as a hallmark of aging inmost somatic tissues, suggesting that DNA
methylation can be used to predict the age of an organism based on tis-
suemethylation proﬁles [38]. Consistently, in DM1methylation levels at
the DMPK locus are lower in adult tissues compared with matching tis-
sues of fetuses [22].
On the other hand, methylation status shows inter and intra-
individual variability not obviously related to the size of n(CTG) intissues [22], and this can explain the lack of correlation between meth-
ylation levels in leukocytes and age found in our cohort of study.
Our data suggest that not only the size but also the structure of the
expanded CTG array would inﬂuence methylation status at DMPK
locus. In fact, in most variants DM1 patients with CCG/CTC/CGG inter-
ruptions, hypermethylation of CpG islands showed an opposite pattern
compared to uninterrupted expanded alleles, occurring exclusively at
the 3′ end of the CTG array.
Since CAG repeats but not CGG repeats can stall the methyltransfer-
ase DNMT1 [39], CGG/CTC/CCG repetitions interspersed into the CTG
array of the variant DM1 alleles might interfere with insulation against
CpGmethylation spreading to downstream regions exerted by the pure
CTG stretch. Intriguingly hypermethylated variant DM1 showed a num-
ber of CGG interruptions along the CTG arraymore abundant compared
to variant unmethylated patients (Table 3). Alternatively, different CCG,
CTC and CGG sequence interruptions within the CTG array might inﬂu-
ence themethylation levels of variant expandedDM1 alleles possibly af-
fecting their higher DNA structure.
Regarding the putative effects of hypermethylation of DM1 locus,
the regions analyzed in this study contains CTCF binding sites which,
at other genomic loci, has been shown to serve as a boundary element
between highly methylated and unmethylated genomic regions impor-
tant for epigenetically regulated processes such as X-inactivation, ge-
netic imprinting or gene transcription [40].
The expanded repeat therefore demarcates an upstream bound-
ary of methylation which could have a functional involvement in
the transcriptional regulation of the entire 19q13.3 region, including
SIX5 and the DMPK gene itself. Data about the expression levels of
DMPK and ﬂanking genes in DM1 tissues are controversial but in
general SIX5 (formerly known as DMHAP) is less affected compared
to DMPK[41–44].
In our study, SIX5was even upregulated and DMPK was reduced in
leukocytes of all DM1 patients compared to controls, but these changes
were independent from themethylation status of the DM1 allele. How-
ever, we cannot exclude that DMPK or SIX5 expression might be specif-
ically impaired by higher methylation levels occurring in tissues other
than leukocytes.
In conclusion,we demonstrated that inherited n(CTG) size and pres-
ence of CCG/CTC/CGG sequence interruptions in the expanded CTG
array are independently associated to hypermethylation at the DMPK
locus in DM1. Hypermethylation of large expanded alleles, described
in our study, may have a functional signiﬁcance as modifying factors
in the phenotype of patients bymodulating local gene expression in dif-
ferent tissues [22,45]. The availability of an additional collection of DM1
tissue samples are needed to clarify this important point.
2652 M. Santoro et al. / Biochimica et Biophysica Acta 1852 (2015) 2645–2652A better understanding of the precise cascade of processes induced
by expanded trinucleotide repeats (TNRs) and, importantly, the starting
point of these changes, could provide therapeutic targets to alleviate
disease progression and limit further TNR expansion.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.09.007.
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